Association Review
In brief
The association between RAD50 (RAD50 Double Strand Break Repair Protein) and Pancreatic Cancer is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
35
Compounds
1
Trials
124of 1,284 via RAD50 compounds
Publications
0
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
1 source summary
A gene summary alongside the source descriptions it was distilled from.
04
Pancreatic Cancer
The disorder
33 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
05
Phenotype
Clinical features
26 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
06
Mechanism overlap
Shared mechanisms
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
07
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
08
Human studies
Clinical trials
1,284 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
09
Provenance
References & sources
8 references
Every source and publication cited across this dossier, as one numbered reference list.
